User Overview

Followers and Following

Followers
Following
Trendsmap

History

Total Followers - Last Year
Daily Follower Change - Last Year
Daily Tweets - Last Year

Tweet Stats

Analysed 638 tweets, tweets from the last 172 weeks.
Tweets Day of Week (UTC)
Tweets Hour of Day (UTC)
Key:
Tweets
Retweets
Quotes
Replies
Tweets Day and Hour Heatmap (UTC)

Tweets

Last 50 tweets from @AlbertBourla
This weekend, I look forward to catching the latest podcast from #TheAntigen, focused on maternal immunization. As we continue our own work in this space, it will be great to hear what experts have to say about these kinds of vaccines.
Season 3 of #TheAntigen podcast is out now! In this 3-part series, we’re diving into maternal immunization. Hear from some of the leading voices in this space to explore how these vaccines work. Listen now 🎧 on your favorite podcast app: on.pfizer.com/3O9xKIP pic.twitter.com/bfL7fTU8be
 
Thank you @matthewherper for an invigorating discussion at #STATSummit about @Pfizer’s efforts to help close the #healthequity gap with our “Accord for a Healthier World,” what’s next on the horizon for Pfizer, and the danger of #COVID19 disinformation.
 
Honored and humbled to accept the “Courage Against Hate Award” at the #NeverIsNow Summit from @ADL. It is high time we raise our voices against antisemitism, racism in all forms and the deliberate spread of hatred. bit.ly/3G2SNLi
Albert Bourla on LinkedIn: Never Is Now Summit Speech
linkedin.com
 
I’m pleased to share data from our trial indicating that our Omicron BA.4/ 5-adapted #COVID19 vaccine continues to generate a strong immune response in adults 30 days after they receive it: on.pfizer.com/3NBx2E7
Replying to @AlbertBourla
Emergency uses of the bivalent vaccine have not been approved or licensed by US FDA but have been authorized to prevent COVID-19 in ages 5yrs+. See Fact Sheets: cvdvaccine-us.com
 
I’m pleased to share data from our trial indicating that our Omicron BA.4/ 5-adapted #COVID19 vaccine continues to generate a strong immune response in adults 30 days after they receive it: on.pfizer.com/3NBx2E7
Early data from our trial evaluating our Omicron BA.4/BA.5-adapted #COVID19 vaccine show increased neutralizing antibodies compared to our Original monovalent vaccine, suggesting it could potentially provide better protection against Omicron BA.4/BA.5: on.pfizer.com/3esniyR
 
Last week, Prevnar 13 received the Silver Medal for Best Vaccine at the 2022 Prix Galien Golden Jubilee Awards. What an amazing recognition for our global team, who have spent decades developing and distributing this vaccine. Congratulations! I am so #PfizerProud of you!
 
176,000 global cases of #MultipleMyeloma are diagnosed each year, and the median life expectancy is ~5 years. Today, we’re one step closer to helping these patients, as we receive Breakthrough Therapy Designation for our investigational treatment: on.pfizer.com/3zJCnU3
 
Together with #BioNTech, we have initiated a Phase 1 study evaluating a potential combined vaccine for influenza and COVID-19 based on #mRNA technology: on.pfizer.com/3UqtkPX
Replying to @AlbertBourla
Worldwide, COVID-19 has caused more than 6.5M deaths, and influenza causes up to 650K deaths each year. If a combined vaccine is successfully developed and licensed, it could simplify immunization practices.
 
Together with #BioNTech, we have initiated a Phase 1 study evaluating a potential combined vaccine for influenza and COVID-19 based on #mRNA technology: on.pfizer.com/3UqtkPX
 
Very proud of both our Q3 financial results & the strong foundation we have built for growth. From RSV, to UC, to migraines—and more, we expect to launch up to 19 new products or indications in the next 18mos to help address a range of patient needs: on.pfizer.com/Q3 $PFE
 
Each year, RSV causes more than 100K child deaths globally. The burden of disease is higher in infants <1yo. Maternal immunization can help, and I’m thrilled to share positive topline data from our trial to develop the first-ever maternal RSV vaccine: on.pfizer.com/3Nobiv
 
Pfizer scientists are using artificial intelligence (AI) & supercomputing to accelerate the delivery of new vaccines & medicines to patients. So I’m proud to join the @CSIS AI Council to develop safe and responsible practices that harness the power of AI to improve healthcare.
NEW: The CSIS AI Council, co-chaired by @JulieSweet and @BradSmi, aims to chart a path forward for corporate responsibility, international collaboration, and effective governance on AI.

Learn more: csis.org/news/csis-laun…
 
I am excited to share that @CDCgov’s Advisory Committee on Immunization Practices has voted to recommend Prevnar-20 to help protect adults previously vaccinated against invasive disease and pneumonia caused by the Streptococcus pneumoniae: on.pfizer.com/3SeWqjD
 
Incredibly proud to have our @Pfizer colleagues lead the conversation about the power of science and share information on our infectious disease work—including vaccines and anti-infectives—at this year’s @IDWeek2022: on.pfizer.com/3gbpnzD
 
Early data from our trial evaluating our Omicron BA.4/BA.5-adapted #COVID19 vaccine show increased neutralizing antibodies compared to our Original monovalent vaccine, suggesting it could potentially provide better protection against Omicron BA.4/BA.5: on.pfizer.com/3esniyR
Replying to @AlbertBourla
Emergency use vaccines have not been approved or licensed by US FDA but have been authorized to prevent COVID-19 in ages 12yrs+ (bivalent) and 6mos+ (monovalent). See Fact Sheets: cvdvaccine-us.com
 
Early data from our trial evaluating our Omicron BA.4/BA.5-adapted #COVID19 vaccine show increased neutralizing antibodies compared to our Original monovalent vaccine, suggesting it could potentially provide better protection against Omicron BA.4/BA.5: on.pfizer.com/3esniyR
I am incredibly proud to share that we have received Emergency Use Authorization from @US_FDA for our Omicron BA.4/BA.5-adapted #COVID19 vaccine for people aged 12 and older: on.pfizer.com/3wIpmIX
 
I’m pleased to share that we have received Emergency Use Authorization from the @US_FDA for our Omicron BA.4/BA.5-adapted #COVID19 vaccine for children aged 5-11. This is an important milestone as we head into the winter months ahead: on.pfizer.com/3MtRKW2
Replying to @AlbertBourla
Emergency uses of the bivalent vaccine have not been approved or licensed by US FDA but have been authorized to prevent COVID-19 in ages 5yrs+. See Fact Sheets: cvdvaccine-us.com
 
I’m pleased to share that we have received Emergency Use Authorization from the @US_FDA for our Omicron BA.4/BA.5-adapted #COVID19 vaccine for children aged 5-11. This is an important milestone as we head into the winter months ahead: on.pfizer.com/3MtRKW2
 
We’ve come a long way since 2020 in reducing #COVID19 hospitalizations & deaths. Among Medicare beneficiaries, for example, we saw a 39-47% reduction in these outcomes due to vaccinations in 2021. Thanks for believing in the power of science!
New ASPE report: “Reduced Deaths & Hospitalizations in Medicare Associated w/COVID-19 Vaccination.” Vaccines linked to 670K fewer hospitalizations & 330K fewer deaths in Medicare in 2021, w/largest reductions during Delta surge. aspe.hhs.gov/reports/reduct… pic.twitter.com/qUeXht5kDK
 
Congratulations to my friend and colleague Angela Hwang for being named on @FortuneMagazine’s 2022 Most Powerful Women in Business list: bit.ly/3UV8B7X
Replying to @AlbertBourla
I feel honored to have had the opportunity to work with Angela for many years and to see firsthand her passion for helping patients, mentoring women and advancing equity as @Pfizer’s Chief Commercial Officer and President of our Global Biopharmaceuticals Business.
 
Congratulations to my friend and colleague Angela Hwang for being named on @FortuneMagazine’s 2022 Most Powerful Women in Business list: bit.ly/3UV8B7X
 
Excited to welcome our new colleagues from Global Blood Therapeutics. Together we’re working to help close the #healthequity gap for #sicklecell disease patients by advancing potential breakthroughs to address the needs of this underserved community: on.pfizer.com/3M9WfEJ
 
Today, we took another step forward in our prostate cancer research, sharing positive topline results from our global trial for metastatic castration-resistant prostate cancer (mCRPC), a disease greatly in need of new solutions: on.pfizer.com/3M3jxMy
Replying to @AlbertBourla
mCRPC is a form of advanced prostate cancer that impacts 10%-20% of men within a few years of their initial diagnosis. These patients need a solution, and we are working hard to target the disease in new, effective ways.
 
Today, we took another step forward in our prostate cancer research, sharing positive topline results from our global trial for metastatic castration-resistant prostate cancer (mCRPC), a disease greatly in need of new solutions: on.pfizer.com/3M3jxMy
 
As flu season approaches, many adults are thinking about ways to help stay healthy. I’m pleased to share that the @US_FDA has approved data on the coadministration of our Prevnar-20 pneumococcal pneumonia vaccine with a flu shot: bit.ly/3rpp0nu
 
A warm welcome to our talented new colleagues from Biohaven! Together, we’re delivering breakthrough treatment options for patients living with migraine: on.pfizer.com/3C2bJX2
 
Latinos account for 18% of the US population but make up only 8% of the STEM workforce. Our colleagues Diego Sacristan, Nathaniel Garcia and Mirna Zaragoza discuss how companies can support Latinos’ careers in our latest LinkedIn Live episode: bit.ly/3SqldlE
Pfizer on LinkedIn: Something's Brewing: Coffee and Conversation | 284 comments
linkedin.com
 
I have tested positive for COVID. I’m feeling well & symptom free. I’ve not had the new bivalent booster yet, as I was following CDC guidelines to wait 3 months since my previous COVID case which was back in mid-August. While we’ve made great progress, the virus is still with us.
 
Our agreement with @GlobalFund for up to 6 million treatment courses of our #COVID19 oral treatment will help to accelerate access for high-risk patients in need across 132 low-and-middle-income countries: on.pfizer.com/3xIMjfu
Replying to @AlbertBourla
Pfizer's oral treatment is not approved, but is authorized for emergency use by the FDA to treat mild-to-moderate COVID-19 in high-risk patients 12+, weighing at least 40 kg, with positive results of SARS-CoV-2 viral testing. See safety info: COVID19oralRx.com.
 
Our agreement with @GlobalFund for up to 6 million treatment courses of our #COVID19 oral treatment will help to accelerate access for high-risk patients in need across 132 low-and-middle-income countries: on.pfizer.com/3xIMjfu
 
I was honored to join our DEI Lead @MonaBabury at @TentOrg’s first-ever #USBusinessSummit, where we—along with 44 other companies—pledged to #HireRefugees over the next 3 years. Welcoming #refugees aligns with Pfizer’s equity value, and we’re excited to help those in need.
 
Parents are often concerned about meningococcal disease, an uncommon but serious illness that can result in death within 24 hours or in long-term disabilities. Today, we announced positive trial results for our pentavalent meningococcal vaccine candidate: on.pfizer.com/3UaBCvP
 
In reply to @AlbertBourla
Currently available flu vaccines typically confer 40%-60% protection. Requiring only the genetic sequence of the #influenza virus, the flexibility of #mRNA technology could potentially allow better matches for seasonal viral strains.
Replying to @AlbertBourla
The flu causes up to 52,000 US deaths annually, disproportionately impacting racial and ethnic minority groups. To help close the #healthequity gap, we aim to achieve representative diversity in our clinical studies so that we can help support everyone’s healthcare journey.
 
I am incredibly excited to share that we are initiating the first Phase 3 study to evaluate the efficacy of our mRNA-based influenza vaccine candidate: on.pfizer.com/3LahWnT
Replying to @AlbertBourla
Currently available flu vaccines typically confer 40%-60% protection. Requiring only the genetic sequence of the #influenza virus, the flexibility of #mRNA technology could potentially allow better matches for seasonal viral strains.
 
I am incredibly excited to share that we are initiating the first Phase 3 study to evaluate the efficacy of our mRNA-based influenza vaccine candidate: on.pfizer.com/3LahWnT
 
Excited to see @POTUS inspiring action through the #CancerMoonshot Initiative. One way or another, cancer touches all our lives, and at @Pfizer, we know we must continue our work to advance breakthroughs to combat these deadly diseases.
 
Today marks the anniversary of #September11. Through actions small or large, in private or for all to see, each of us can honor the brave souls we lost—and those who rushed to help their fellow citizens that day—by being agents of kindness and good will with our words & actions.
 
Alopecia areata is an autoimmune disease that causes hair to fall out, affecting around 147 million people globally. We’re working to develop a potential treatment, and I’m happy to share that the FDA and EMA have accepted our submissions: on.pfizer.com/3L8CPQo
 
On behalf of all my Pfizer colleagues, I share our deepest condolences to the people of the United Kingdom, the Commonwealth and the Royal Family on the passing of Her Majesty Queen Elizabeth II.
Replying to @AlbertBourla
She served as a calm and unifying presence for her people throughout some of the world’s most historic events. As this era comes to an end, we send our warmest wishes to His Majesty King Charles III as he begins his reign, one undoubtedly strengthened by his mother’s example.
 
On behalf of all my Pfizer colleagues, I share our deepest condolences to the people of the United Kingdom, the Commonwealth and the Royal Family on the passing of Her Majesty Queen Elizabeth II.
 
This week a shipment of @Pfizer patented medicines & vaccines to treat & prevent life-threatening infectious diseases, inflammatory disease & certain cancers arrived in #Rwanda under An Accord for a Healthier World. We are working together to close the #healthequity gap!
The Ministry of Health has received eight categories of Pfizer medicines and vaccines for infectious and inflammatory diseases and certain cancers through ‘An Accord for a Healthier World’ signed between the Government of Rwanda and @pfizer. pic.twitter.com/W0pyKzWwck
 
We need sufficient testing & diagnosis to enable timely & equitable access to COVID treatments. Pfizer is proud to support the Quick Start Consortium through financial commitment & donation of our oral treatment to support scale-up for countries in need. bit.ly/3BgQaCD
 
About 1 in 4 pregnant women carry Group B Streptococcus bacteria that can be passed to their babies, resulting in 147,000+ infant deaths worldwide each year. Today, @US_FDA granted Breakthrough Therapy Designation for our maternal vaccine candidate: on.pfizer.com/3TMoOvr
Replying to @AlbertBourla
With an estimated 410,000 GBS cases worldwide—the largest burden in low- and middle-income countries—we are pursuing a global clinical development strategy with the intent to make a successfully developed vaccine available worldwide as quickly as possible.
 
About 1 in 4 pregnant women carry Group B Streptococcus bacteria that can be passed to their babies, resulting in 147,000+ infant deaths worldwide each year. Today, @US_FDA granted Breakthrough Therapy Designation for our maternal vaccine candidate: on.pfizer.com/3TMoOvr
 
Today, the EMA CHMP adopted a positive opinion recommending our Omicron BA.1-adapted #COVID19 vaccine booster, potentially providing Europeans with another solution to address the ongoing challenges of this disease: on.pfizer.com/3R6NT2p
Replying to @AlbertBourla
Emergency uses of the Bivalent vaccine have not been approved or licensed by US FDA but have been authorized to prevent COVID-19 in ages 12yrs+. See Fact Sheets: cvdvaccine-us.com
 
Today, the EMA CHMP adopted a positive opinion recommending our Omicron BA.1-adapted #COVID19 vaccine booster, potentially providing Europeans with another solution to address the ongoing challenges of this disease: on.pfizer.com/3R6NT2p
 
In reply to @AlbertBourla
As Americans prepare for the coming fall and winter seasons, this adapted vaccine will be an important tool, as #COVID19 caused by existing and emerging variants could surge.
Replying to @AlbertBourla
Emergency uses of the Bivalent vaccine have not been approved or licensed by US FDA but have been authorized to prevent COVID-19 in ages 12yrs+. See Fact Sheets: cvdvaccine-us.com
 
I am incredibly proud to share that we have received Emergency Use Authorization from @US_FDA for our Omicron BA.4/BA.5-adapted #COVID19 vaccine for people aged 12 and older: on.pfizer.com/3wIpmIX
Replying to @AlbertBourla
As Americans prepare for the coming fall and winter seasons, this adapted vaccine will be an important tool, as #COVID19 caused by existing and emerging variants could surge.
 
I am incredibly proud to share that we have received Emergency Use Authorization from @US_FDA for our Omicron BA.4/BA.5-adapted #COVID19 vaccine for people aged 12 and older: on.pfizer.com/3wIpmIX
 
There are currently no vaccines to help protect older adults from RSV, so I am pleased to share positive data from our Phase 3 trial investigating the first potential bivalent RSV vaccine for these people: on.pfizer.com/3cfSK2l
 
 
For access to this functionality a Trendsmap Explore subscription is required.

A Trendsmap Explore subscription provides full access to all available timeframes

Find out more

Thanks for trying our Trendsmap Pro demo.

For continued access, and to utliise the full functionality available, you'll need to subscribe to a Trendsmap Pro subscription.

Find out more

This account is already logged in to Trendsmap.
Your subscription allows access for one user. If you require access for more users, you can create additional subscriptions.
Please Contact us if you are interested in discussing discounts for 3+ users for your organisation, or have any other queries.